A new article from Leyden Labs has been published in Scientific Reports that showcases the potential advantages of intranasal administration of monoclonal antibodies over systemic administration to protect against airborne viruses.
The ongoing spread of avian flu among animals has increased the urgency of developing products that could prevent infection in the event of an H5N1 pandemic. A new study by Leyden Labs, published in Nature’s Scientific Reports, shows that the CR9114 antibody can protect intranasally at low dosages against H5N1 in vivo.
A new article from Leyden Labs has been published in the European Journal of Epidemiology, titled "SARS‑CoV‑2 elicits non‑sterilizing immunity and evades vaccine‑induced immunity: implications for future vaccination strategies.”
Recently, our article entitled “The influenza hemagglutinin stem antibody CR9114: Evidence for a narrow evolutionary path towards universal protection,” appeared in a special issue of Frontiers in Virology on the role of genetic and structural insights of neutralizing antibodies to guide viral vaccine design.
A new research article by Leyden Labs and partners at Imperial College has been published in Infectious Diseases & Therapy.
OUR NEW APPROACH | OUR TEAM | JOIN OUR MISSION | NEWS | CAREERS
Leyden Laboratories B.V.
Leiden Laboratory
Emmy Noetherweg 2
2333 BK Leiden
The Netherlands
Leyden Labs Asia Pte. Ltd.
79 Science Park Drive
#04-05, Cintech IV
Singapore 118264
© Leyden Labs, 2023 | Privacy Statement | Design by Ape to Zebra